home > drugs a-z list > vectibix (panitumumab injection for intravenous use) drug center > vectibix (panitumumab injection for intravenous use) drug - medication guide and patient information

Advise patients to contact a healthcare professional for any of the following:

• Skin and ocular/visual changes [see BOXED WARNING and WARNINGS AND PRECAUTIONS,
• Signs and symptoms of infusion reactions including fever, chills, or breathing problems [see BOXED WARNING and WARNINGS AND PRECAUTIONS],
• Persistent or recurrent coughing, wheezing, dyspnea, or new onset facial swelling [see WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS],
• Pregnancy or nursing [see Use in Specific Populations].

Advise patients of the need for:

• Periodic monitoring of electrolytes [see WARNINGS AND PRECAUTIONS],
• Limitation of sun exposure (use sunscreen, wear hats) while receiving Vectibix (panitumumab injection for intravenous use) and for 2 months after the last dose of Vectibix therapy. [see WARNINGS AND PRECAUTIONS],
• Adequate contraception in both males and females while receiving Vectibix (panitumumab injection for intravenous use) and for 6 months after the last dose of Vectibix therapy [see Use in Specific Populations].
• Vectibix® (panitumumab) Injection for Intravenous Use

Last reviewed on RxList: 8/5/2009
This monograph has been modified to include the generic and brand name in many instances.